Angion_2IN-02.jpg
Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
September 08, 2021 00:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
July 07, 2021 07:30 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report First Quarter 2021 Financial Results
May 03, 2021 07:00 ET | FibroGen, Inc
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close. FibroGen will also...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at Upcoming Investor Conference
April 28, 2021 07:00 ET | FibroGen, Inc
SAN FRANCISCO, April 28, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
February 18, 2021 07:00 ET | FibroGen, Inc
SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close....
TreviLogo.png
Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™
October 21, 2020 08:00 ET | Trevi Therapeutics
Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF Phase 2b/3 PRISM Trial of Haduvio for Severe Pruritus in Patients with Prurigo Nodularis Reaches 50% Enrollment...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Second Quarter 2020 Financial Results
July 23, 2020 07:00 ET | FibroGen, Inc
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
May 08, 2020 07:00 ET | FibroGen, Inc
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
March 02, 2020 16:01 ET | FibroGen, Inc
Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic...
cohbar.JPG
CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis
December 16, 2019 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...